If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt Diag Hld Regulatory News (IDHC)

Share Price Information for Int Diag Hld (IDHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.328
Bid: 0.316
Ask: 0.34
Change: 0.01 (3.14%)
Spread: 0.024 (7.595%)
Open: 0.318
High: 0.00
Low: 0.00
Prev. Close: 0.318
IDHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

7 Sep 2022 16:04

RNS Number : 6649Y
Integrated Diagnostics Holdings PLC
07 September 2022
 

Integrated Diagnostics Holdings Plc Notice of Results

 

7 September 2022

 

(London) Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria, will publish its results for the six-month period ended 30 June 2022 on Monday, 12 September 2022 at 7am (UK).

 

An analyst and investor call will be hosted at 2pm (UK) | 3pm (Egypt) on Tuesday, 13 September 2022. You can register for the call by clicking on this link, and you may dial in using the conference call details below:

 

· Webinar ID: 928 3447 8622

· Webinar Passcode: 651028

 

For more information about the event, please contact: amr.amin@cicapital.com

 

-Ends-

 

About Integrated Diagnostics Holdings (IDH)

IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 2,000 diagnostics tests. From its base of 520 branches as of 31 March 2022, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern, African, and East Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015 with a secondary listing on the EGX since May 2021 (ticker: IDHC.CA). Learn more at idhcorp.com.

 

The person responsible for arranging the release of this announcement is Nancy Fahmy, Investor Relations Director at IDH.

 

Contact

Nancy Fahmy

Investor Relations Director

T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 | nancy.fahmy@idhcorp.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORGZGGLKNMGZZM
Date   Source Headline
9th Aug 20184:35 pmRNSPrice Monitoring Extension
5th Jul 20184:35 pmRNSPrice Monitoring Extension
15th May 20187:00 amRNSTrading Statement
14th May 20184:25 pmRNSResult of AGM
11th May 20184:46 pmRNSHolding(s) in Company
25th Apr 20184:35 pmRNSPrice Monitoring Extension
19th Apr 20185:04 pmRNSAnnual Financial Report & Notice of AGM
12th Apr 201812:08 pmRNSSecond Price Monitoring Extn
12th Apr 201812:02 pmRNSPrice Monitoring Extension
9th Apr 201812:07 pmRNSSecond Price Monitoring Extn
9th Apr 201812:02 pmRNSPrice Monitoring Extension
3rd Apr 20184:40 pmRNSSecond Price Monitoring Extn
3rd Apr 20184:35 pmRNSPrice Monitoring Extension
28th Mar 201811:54 amRNSHolding(s) in Company
21st Mar 20187:00 amRNSFinal Results
26th Feb 20189:49 amRNSAward from the College of American Pathologists
1st Dec 20177:52 amRNSInvestment in Nigeria's Echo-Scan
22nd Nov 20177:00 amRNSTrading Update
22nd Sep 20173:29 pmRNSHolding(s) in Company
22nd Aug 20177:00 amRNSHalf-year Report
16th Jun 20174:42 pmRNSSecond Price Monitoring Extn
16th Jun 20174:35 pmRNSPrice Monitoring Extension
23rd May 20177:00 amRNSTrading Statement
22nd May 20174:22 pmRNSResult of AGM
27th Apr 20171:12 pmRNSAnnual Financial Report
22nd Mar 20177:00 amRNSFinal Results
10th Mar 20172:55 pmRNSHolding(s) in Company
28th Feb 20174:40 pmRNSSecond Price Monitoring Extn
28th Feb 20174:35 pmRNSPrice Monitoring Extension
23rd Nov 20167:00 amRNSTrading Statement
3rd Nov 20162:02 pmRNSVice President of Finance and Strategy Appointment
23rd Aug 20167:00 amRNSHalf-year Report
6th Jul 201612:07 pmRNSSecond Price Monitoring Extn
6th Jul 201612:02 pmRNSPrice Monitoring Extension
27th Jun 20164:35 pmRNSPrice Monitoring Extension
1st Jun 20164:35 pmRNSPrice Monitoring Extension
11th May 20167:00 amRNSUpdate on Q1 2016 Results
9th May 20164:03 pmRNSResult of AGM
26th Apr 20164:40 pmRNSSecond Price Monitoring Extn
26th Apr 20164:35 pmRNSPrice Monitoring Extension
18th Apr 20163:23 pmRNSAnnual Financial Report
29th Mar 20167:00 amRNSFinal Results
16th Mar 20164:40 pmRNSSecond Price Monitoring Extn
16th Mar 20164:35 pmRNSPrice Monitoring Extension
30th Dec 20154:40 pmRNSSecond Price Monitoring Extn
30th Dec 20154:35 pmRNSPrice Monitoring Extension
7th Dec 20153:59 pmRNSHolding(s) in Company
23rd Nov 20157:00 amRNSTrading Statement
20th Oct 20154:40 pmRNSSecond Price Monitoring Extn
20th Oct 20154:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.